Eleonor Borja 10/11/26 Eleonor Borja 10/11/26 Microdosing Benefits May Be Limited to Dosing Days. What the Largest Daily-Diary Study Found. Read More Eleonor Borja 10/6/26 Eleonor Borja 10/6/26 Psilocybin Protected Nerves From Chemotherapy in Mice. Human Evidence Comes Next. Read More Eleonor Borja 10/3/26 Eleonor Borja 10/3/26 Who Is Ready to Deliver Psychedelic Care? Lisa Ginzburg of Changa Institute Brings Training and Credentialing to the FDA Read More Eleonor Borja 9/27/26 Eleonor Borja 9/27/26 The VA’s New Psilocybin Trial Moves Veteran Care Into a More Consequential Phase of Research Read More Eleonor Borja 9/20/26 Eleonor Borja 9/20/26 Psilocybin Produced Higher Smoking Quit Rates Than Nicotine Patches in a Pilot Trial Read More Eleonor Borja 9/13/26 Eleonor Borja 9/13/26 Psilocybin Therapy Shows Promise for Anorexia Nervosa in Early Clinical Study Read More Eleonor Borja 9/6/26 Eleonor Borja 9/6/26 Psychedelic Medicine Is Moving Toward Clinical Practice. State Systems Can Help Lead the Way. Read More Eleonor Borja 8/30/26 Eleonor Borja 8/30/26 What Predicts a Better Outcome in Psychedelic-Assisted Therapy? Read More Eleonor Borja 8/23/26 Eleonor Borja 8/23/26 Changa Institute Adds New Mexico Psilocybin Certification Training for Licensed Professionals Read More Eleonor Borja 8/16/26 Eleonor Borja 8/16/26 Psilocybin and Longevity: Promising Data, Early Interpretations Read More Eleonor Borja 8/10/26 Eleonor Borja 8/10/26 Psilocybin and Neuroplasticity: New Human Data Suggests Setting May Matter More Than We Thought Read More Eleonor Borja 7/31/26 Eleonor Borja 7/31/26 Oregon Psilocybin Services Data: What Clinicians Need to Know Read More Eleonor Borja 7/22/26 Eleonor Borja 7/22/26 What Eli Lilly’s $3.8 Billion AtaiBeckley Deal Means for Psychedelic Medicine Read More Eleonor Borja 7/13/26 Eleonor Borja 7/13/26 Add Your Voice to the FDA’s September 2026 Public Hearing on Psychedelics Read More Eleonor Borja 7/7/26 Eleonor Borja 7/7/26 Psilocybin, Alzheimer’s Disease, and Psychedelic Practice: Why One 2026 Case Report Requires Caution Read More Lisa Ginzburg 6/23/26 Lisa Ginzburg 6/23/26 The Science and History of Psychedelics: How They Work and Where the Research Stands in 2026 Read More Eleonor Borja 6/9/26 Eleonor Borja 6/9/26 Australia Just Expanded Psychedelic Therapy Access, and Raised the Bar for Practitioners Read More Eleonor Borja 5/28/26 Eleonor Borja 5/28/26 Psilocybin for Treatment-Resistant Depression in 2026: What the Latest Phase 3 Research Means for Psychedelic Therapy Careers Read More Eleonor Borja 3/24/26 Eleonor Borja 3/24/26 How to Start a Psilocybin Facilitation Practice in 2026: The Complete Step-by-Step Guide Read More Eleonor Borja 3/21/26 Eleonor Borja 3/21/26 Spiritual Stewardship and Clinical Science: Why the Best Psilocybin Facilitators Hold Both Read More Older Posts
Eleonor Borja 10/11/26 Eleonor Borja 10/11/26 Microdosing Benefits May Be Limited to Dosing Days. What the Largest Daily-Diary Study Found. Read More
Eleonor Borja 10/6/26 Eleonor Borja 10/6/26 Psilocybin Protected Nerves From Chemotherapy in Mice. Human Evidence Comes Next. Read More
Eleonor Borja 10/3/26 Eleonor Borja 10/3/26 Who Is Ready to Deliver Psychedelic Care? Lisa Ginzburg of Changa Institute Brings Training and Credentialing to the FDA Read More
Eleonor Borja 9/27/26 Eleonor Borja 9/27/26 The VA’s New Psilocybin Trial Moves Veteran Care Into a More Consequential Phase of Research Read More
Eleonor Borja 9/20/26 Eleonor Borja 9/20/26 Psilocybin Produced Higher Smoking Quit Rates Than Nicotine Patches in a Pilot Trial Read More
Eleonor Borja 9/13/26 Eleonor Borja 9/13/26 Psilocybin Therapy Shows Promise for Anorexia Nervosa in Early Clinical Study Read More
Eleonor Borja 9/6/26 Eleonor Borja 9/6/26 Psychedelic Medicine Is Moving Toward Clinical Practice. State Systems Can Help Lead the Way. Read More
Eleonor Borja 8/30/26 Eleonor Borja 8/30/26 What Predicts a Better Outcome in Psychedelic-Assisted Therapy? Read More
Eleonor Borja 8/23/26 Eleonor Borja 8/23/26 Changa Institute Adds New Mexico Psilocybin Certification Training for Licensed Professionals Read More
Eleonor Borja 8/16/26 Eleonor Borja 8/16/26 Psilocybin and Longevity: Promising Data, Early Interpretations Read More
Eleonor Borja 8/10/26 Eleonor Borja 8/10/26 Psilocybin and Neuroplasticity: New Human Data Suggests Setting May Matter More Than We Thought Read More
Eleonor Borja 7/31/26 Eleonor Borja 7/31/26 Oregon Psilocybin Services Data: What Clinicians Need to Know Read More
Eleonor Borja 7/22/26 Eleonor Borja 7/22/26 What Eli Lilly’s $3.8 Billion AtaiBeckley Deal Means for Psychedelic Medicine Read More
Eleonor Borja 7/13/26 Eleonor Borja 7/13/26 Add Your Voice to the FDA’s September 2026 Public Hearing on Psychedelics Read More
Eleonor Borja 7/7/26 Eleonor Borja 7/7/26 Psilocybin, Alzheimer’s Disease, and Psychedelic Practice: Why One 2026 Case Report Requires Caution Read More
Lisa Ginzburg 6/23/26 Lisa Ginzburg 6/23/26 The Science and History of Psychedelics: How They Work and Where the Research Stands in 2026 Read More
Eleonor Borja 6/9/26 Eleonor Borja 6/9/26 Australia Just Expanded Psychedelic Therapy Access, and Raised the Bar for Practitioners Read More
Eleonor Borja 5/28/26 Eleonor Borja 5/28/26 Psilocybin for Treatment-Resistant Depression in 2026: What the Latest Phase 3 Research Means for Psychedelic Therapy Careers Read More
Eleonor Borja 3/24/26 Eleonor Borja 3/24/26 How to Start a Psilocybin Facilitation Practice in 2026: The Complete Step-by-Step Guide Read More
Eleonor Borja 3/21/26 Eleonor Borja 3/21/26 Spiritual Stewardship and Clinical Science: Why the Best Psilocybin Facilitators Hold Both Read More
